The differences in diabetes risk between statins appear similar across men and women, older and younger people, those with or without obesity, and those with higher or lower cholesterol, meaning the pattern holds for most patients with heart disease.
Claim Context
The association between statin type and new-onset diabetes risk is consistent across subgroups including age, sex, BMI, smoking status, and baseline LDL-C, suggesting that the differential metabolic effects are broadly applicable rather than limited to specific patient subpopulations.
“Subgroup analyses were performed according to predefined variables, including age, sex, baseline LDL-C, smoking status, alcohol intake, and BMI. The association between moderate-intensity statins and NODM risk appeared generally similar across subgroups, and no statistically significant interaction effects were detected.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of individual patient data could determine whether statin-specific diabetes risk differences are consistent across subgroups in diverse populations.
A systematic review and meta-analysis of individual participant data from RCTs and large cohorts comparing statin types, stratifying by age, sex, BMI, baseline glucose, and ethnicity, with diabetes incidence as outcome and interaction testing for each subgroup.
An RCT with prespecified subgroup analyses could determine whether statin-specific diabetes risk varies by baseline metabolic status.
A multicenter RCT of 4,000 adults with ASCVD, stratified by BMI (<25 vs. ≥25), fasting glucose (<100 vs. 100–125 mg/dL), and sex, randomized to atorvastatin vs. rosuvastatin, with diabetes incidence as primary outcome and interaction testing for each subgroup.
A prospective cohort with detailed baseline phenotyping could confirm whether statin-specific diabetes risk is consistent across metabolic subgroups.
A prospective cohort of 12,000 adults with ASCVD, with baseline measurements of insulin resistance, visceral fat, and genetic risk scores, followed for 5 years to assess diabetes incidence by statin type within predefined subgroups.
A case-control study could determine whether the association between statin type and diabetes differs in patients with prediabetes versus normoglycemia.
A case-control study comparing 800 patients who developed diabetes on statins to 800 matched controls, stratified by baseline prediabetes status, and testing for interaction between statin type and glucose category.
A cross-sectional analysis could reveal whether HbA1c levels differ by statin type within subgroups defined by BMI or age.
A cross-sectional analysis of 15,000 adults with ASCVD on statins, measuring HbA1c and stratifying by statin type, BMI category, and age group (≤60 vs. >60).